Literature DB >> 28490570

Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors.

Julia E Draper1, Patrycja Sroczynska1,2,3, Hui Sun Leong4, Muhammad Z H Fadlullah1, Crispin Miller4, Valerie Kouskoff5, Georges Lacaud1.   

Abstract

RUNX1 is crucial for the regulation of megakaryocyte specification, maturation, and thrombopoiesis. Runx1 possesses 2 promoters: the distal P1 and proximal P2 promoters. The major protein isoforms generated by P1 and P2 are RUNX1C and RUNX1B, respectively, which differ solely in their N-terminal amino acid sequences. RUNX1C is the most abundantly expressed isoform in adult hematopoiesis, present in all RUNX1-expressing populations, including the cKit+ hematopoietic stem and progenitor cells. RUNX1B expression is more restricted, being highly expressed in the megakaryocyte lineage but downregulated during erythropoiesis. We generated a Runx1 P1 knock-in of RUNX1B, termed P1-MRIPV This mouse line lacks RUNX1C expression but has normal total RUNX1 levels, solely comprising RUNX1B. Using this mouse line, we establish a specific requirement for the P1-RUNX1C isoform in megakaryopoiesis, which cannot be entirely compensated for by RUNX1B overexpression. P1 knock-in megakaryocyte progenitors have reduced proliferative capacity and undergo increased cell death, resulting in thrombocytopenia. P1 knock-in premegakaryocyte/erythroid progenitors demonstrate an erythroid-specification bias, evident from increased erythroid colony-forming ability and decreased megakaryocyte output. At a transcriptional level, multiple erythroid-specific genes are upregulated and megakaryocyte-specific transcripts are downregulated. In addition, proapoptotic pathways are activated in P1 knock-in premegakaryocyte/erythroid progenitors, presumably accounting for the increased cell death in the megakaryocyte progenitor compartment. Unlike in the conditional adult Runx1 null models, megakaryocytic maturation is not affected in the P1 knock-in mice, suggesting that RUNX1B can regulate endomitosis and thrombopoiesis. Therefore, despite the high degree of structural similarity, RUNX1B and RUNX1C isoforms have distinct and specific roles in adult megakaryopoiesis.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28490570      PMCID: PMC5833261          DOI: 10.1182/blood-2016-06-723635

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  47 in total

1.  Alternative Runx1 promoter usage in mouse developmental hematopoiesis.

Authors:  Thomas Bee; Kate Liddiard; Gemma Swiers; Sorrel R B Bickley; Chris S Vink; Andrew Jarratt; Jim R Hughes; Alexander Medvinsky; Marella F T R de Bruijn
Journal:  Blood Cells Mol Dis       Date:  2009-05-21       Impact factor: 3.039

2.  Identification of an alternatively spliced form of the mouse AML1/RUNX1 gene transcript AML1c and its expression in early hematopoietic development.

Authors:  Y Fujita; M Nishimura; M Taniwaki; T Abe; T Okuda
Journal:  Biochem Biophys Res Commun       Date:  2001-03       Impact factor: 3.575

3.  Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia.

Authors:  W J Song; M G Sullivan; R D Legare; S Hutchings; X Tan; D Kufrin; J Ratajczak; I C Resende; C Haworth; R Hock; M Loh; C Felix; D C Roy; L Busque; D Kurnit; C Willman; A M Gewirtz; N A Speck; J H Bushweller; F P Li; K Gardiner; M Poncz; J M Maris; D G Gilliland
Journal:  Nat Genet       Date:  1999-10       Impact factor: 38.330

4.  Runx1 is essential for hematopoietic commitment at the hemangioblast stage of development in vitro.

Authors:  Georges Lacaud; Lia Gore; Marion Kennedy; Valerie Kouskoff; Paul Kingsley; Christopher Hogan; Leif Carlsson; Nancy Speck; James Palis; Gordon Keller
Journal:  Blood       Date:  2002-07-15       Impact factor: 22.113

5.  Differentiation-dependent interactions between RUNX-1 and FLI-1 during megakaryocyte development.

Authors:  Hui Huang; Ming Yu; Thomas E Akie; Tyler B Moran; Andrew J Woo; Nathan Tu; Zachary Waldon; Yin Yin Lin; Hanno Steen; Alan B Cantor
Journal:  Mol Cell Biol       Date:  2009-05-26       Impact factor: 4.272

6.  AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis.

Authors:  Motoshi Ichikawa; Takashi Asai; Toshiki Saito; Sachiko Seo; Ieharu Yamazaki; Tetsuya Yamagata; Kinuko Mitani; Shigeru Chiba; Seishi Ogawa; Mineo Kurokawa; Hisamaru Hirai
Journal:  Nat Med       Date:  2004-02-15       Impact factor: 53.440

7.  AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis.

Authors:  T Okuda; J van Deursen; S W Hiebert; G Grosveld; J R Downing
Journal:  Cell       Date:  1996-01-26       Impact factor: 41.582

8.  Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions.

Authors:  Kira Behrens; Ioanna Triviai; Maike Schwieger; Nilgün Tekin; Malik Alawi; Michael Spohn; Daniela Indenbirken; Marion Ziegler; Ursula Müller; Warren S Alexander; Carol Stocking
Journal:  Blood       Date:  2016-04-13       Impact factor: 22.113

9.  Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter.

Authors:  Michael J Chen; Tomomasa Yokomizo; Brandon M Zeigler; Elaine Dzierzak; Nancy A Speck
Journal:  Nature       Date:  2009-01-07       Impact factor: 49.962

10.  Cell-autonomous function of Runx1 transcriptionally regulates mouse megakaryocytic maturation.

Authors:  Niv Pencovich; Ram Jaschek; Joseph Dicken; Ayelet Amit; Joseph Lotem; Amos Tanay; Yoram Groner
Journal:  PLoS One       Date:  2013-05-23       Impact factor: 3.240

View more
  8 in total

1.  MicroRNA-9 promotes cell proliferation by regulating RUNX1 expression in human megakaryocyte development.

Authors:  Sanjeev Raghuwanshi; Usha Gutti; Ravinder Kandi; Ravi Kumar Gutti
Journal:  Cell Prolif       Date:  2017-11-28       Impact factor: 6.831

Review 2.  Myeloid neoplasms and clonal hematopoiesis from the RUNX1 perspective.

Authors:  Yoshihiro Hayashi; Yuka Harada; Hironori Harada
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 11.528

Review 3.  Transcription factor mutations as a cause of familial myeloid neoplasms.

Authors:  Jane E Churpek; Emery H Bresnick
Journal:  J Clin Invest       Date:  2019-02-01       Impact factor: 14.808

4.  A novel prospective isolation of murine fetal liver progenitors to study in utero hematopoietic defects.

Authors:  Julia E Draper; Patrycja Sroczynska; Muhammad Z H Fadlullah; Rahima Patel; Gillian Newton; Wolfgang Breitwieser; Valerie Kouskoff; Georges Lacaud
Journal:  PLoS Genet       Date:  2018-01-04       Impact factor: 5.917

5.  Regulation of RUNX1 dosage is crucial for efficient blood formation from hemogenic endothelium.

Authors:  Michael Lie-A-Ling; Elli Marinopoulou; Andrew J Lilly; Mairi Challinor; Rahima Patel; Christophe Lancrin; Valerie Kouskoff; Georges Lacaud
Journal:  Development       Date:  2018-03-12       Impact factor: 6.868

Review 6.  RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.

Authors:  Emiel van der Kouwe; Philipp Bernhard Staber
Journal:  Int J Mol Sci       Date:  2019-01-16       Impact factor: 5.923

Review 7.  Transcriptional control of blood cell emergence.

Authors:  Sara Menegatti; Marcel de Kruijf; Eva Garcia-Alegria; Georges Lacaud; Valerie Kouskoff
Journal:  FEBS Lett       Date:  2019-08-31       Impact factor: 4.124

8.  Slc35a1 deficiency causes thrombocytopenia due to impaired megakaryocytopoiesis and excessive platelet clearance in the liver.

Authors:  Xiaolin Ma; Yun Li; Yuji Kondo; Huiping Shi; Jingjing Han; Yizhi Jiang; Xia Bai; Stephanie A Archer-Hartmann; Parastoo Azadi; Changgeng Ruan; Jianxin Fu; Lijun Xia
Journal:  Haematologica       Date:  2021-03-01       Impact factor: 9.941

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.